Clinical trial
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent…
NCT00184015 · University of Southern California, Other · Unknown status
Key facts
| NCT number | NCT00184015 |
|---|---|
| Title | Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) |
| Lead sponsor | University of Southern California, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab and Bortezomib |
| Enrollment | 50 |
| Start date | Aug 18, 2005 |
| Primary completion | Aug 21, 2016 |
| Completion | Aug 21, 2018 |
| First posted | Sep 16, 2005 |
| Last update posted | Apr 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: